<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130831</url>
  </required_header>
  <id_info>
    <org_study_id>SPD405-702</org_study_id>
    <nct_id>NCT01130831</nct_id>
  </id_info>
  <brief_title>Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy</brief_title>
  <official_title>A Phase IV, Multi-Centre, Non-interventional Study Evaluating the Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium Based Phosphate Binder Therapy on Serum Phosphorous Control, Concomitant Vitamin D Therapy and Bone Related Biochemical Parameters in End Stage Renal Disease Patients on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      To assess the percentage of patients on lanthanum carbonate, that achieve Kidney Disease
      Outcome Quality Initiative (KDOQI) guideline suggested values for serum phosphorous in
      patients previously treated with calcium-based phosphate binder therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Subjects That Achieved Controlled Serum Phosphorous Levels on Calcium-based Phosphate Binder Therapy</measure>
    <time_frame>Baseline</time_frame>
    <description>Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Subjects That Achieved Controlled Serum Phosphorous Levels on Lanthanum Carbonate</measure>
    <time_frame>12 months</time_frame>
    <description>Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects That Achieved Controlled Serum Calcium Levels on Calcium-based Phosphate Binder Therapy</measure>
    <time_frame>Baseline</time_frame>
    <description>Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects That Achieved Controlled Serum Calcium Levels on Lanthanum Carbonate Therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects That Achieved Controlled Serum Calcium-Phosphorous Product Levels on Calcium-based Phosphate Binder Therapy</measure>
    <time_frame>Baseline</time_frame>
    <description>Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of &lt;55 mg^2/dL^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects That Achieved Controlled Serum Calcium-Phosphorous Product Levels on Lanthanum Carbonate Therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of &lt;55 mg^2/dL^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects That Maintained Control of Serum Phosphorous Levels on Lanthanum Carbonate</measure>
    <time_frame>12 months</time_frame>
    <description>Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects That Maintained Control of Serum Calcium Levels on Lanthanum Carbonate</measure>
    <time_frame>12 months</time_frame>
    <description>Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects That Maintained Control of Serum Calcium-Phosphorous Product Levels on Lanthanum Carbonate Therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of &lt;55 mg^2/dL^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects That Maintained Control of Intact Parathyroid Hormone (iPTH) Levels on Lanthanum Carbonate Therapy</measure>
    <time_frame>12 months</time_frame>
    <description>iPTH levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for iPTH of 150-300 pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Phosphorous Levels at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Calcium Levels at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Calcium-Phosphorous Product Levels at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in iPTH Levels at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in 25-Hydroxy Vitamin D Levels at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in 1,25-Hydroxy Vitamin D Levels at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Hypocalcemic Events on Calcium-based Phosphate Binder Therapy</measure>
    <time_frame>Baseline</time_frame>
    <description>Hypocalcemia is defined as serum calcium levels below 8.02 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Hypocalcemic Events on Lanthanum Carbonate</measure>
    <time_frame>12 months</time_frame>
    <description>Hypocalcemia is defined as serum calcium levels below 8.02 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Hypercalcemic Events on Calcium-based Phosphate Binder Therapy</measure>
    <time_frame>Baseline</time_frame>
    <description>Hypercalcemia is defined as total serum calcium level above 11.22 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Hypercalcemic Events on Lanthanum Carbonate</measure>
    <time_frame>12 months</time_frame>
    <description>Hypercalcemia defined as total serum calcium above 11.22 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vitamin D Dose at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Total Daily Dose of Calcium at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Tablets Per Day</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">66</enrollment>
  <condition>End Stage Renal Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum carbonate</intervention_name>
    <other_name>Fosrenol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Haemodialysis patients with hyperphosphataemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients meeting all of the criteria listed below may be included in the study:

          1. Patients aged over 18 years

          2. Patients with ESRD on haemodialysis who are willing and able to provide written
             informed consent.

          3. Patients on:

               -  Lanthanum carbonate monotherapy for ≥1 month

               -  Lanthanum carbonate monotherapy for ≤3 months

               -  Calcium-based monotherapy for ≥3 months immediately prior to lanthanum carbonate
                  therapy.

          4. Values recorded in medical records detailing serum phosphorous, serum
             calcium-phosphorus product, iPTH, and medication ≤6 months prior to commencing
             lanthanum carbonate therapy and whilst on a calcium-based monotherapy.

        Exclusion Criteria:

        Patients are excluded from the study if any of the following criteria are met at screening:

          1. Known or suspected intolerance or hypersensitivity to lanthanum, or any of the stated
             ingredients

          2. Patients with known hypophosphatemia (phosphate level below lower level of normal)

          3. Patients with severe hepatic impairment

          4. Patients with requirement for calcium supplementation for reasons other than CKD

          5. Pregnant or lactating women and women planning to become pregnant over the next 12
             months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dialyse Alsfeld</name>
      <address>
        <city>Alsfeld</city>
        <zip>36304</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologische Praxis Altötting-Burghausen</name>
      <address>
        <city>Altötting</city>
        <zip>84503</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyse am Treptower Park</name>
      <address>
        <city>Berlin</city>
        <zip>12435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyse Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Cochem</name>
      <address>
        <city>Cochem</city>
        <zip>56812</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Coesfeld</name>
      <address>
        <city>Coesfeld</city>
        <zip>48653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Caspar-David-Friedrich-Str.</name>
      <address>
        <city>Dresden</city>
        <zip>01217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Karlstraße</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Süd</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH-Nierenzentrum Eberswalde</name>
      <address>
        <city>Eberswalde</city>
        <zip>16225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arzt für Dialyse, Facharzt für Innere Medizin und Nephrologie</name>
      <address>
        <city>Essen</city>
        <zip>45127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Lauerwald</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Grevenbroich</name>
      <address>
        <city>Grevenbroich</city>
        <zip>41516</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyse im Heidering</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxen Herne und Wanne-Eickel</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyse Herzberg</name>
      <address>
        <city>Herzberg</city>
        <zip>04916</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patienten-Heimversorgung</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Facharzt für Innere Medizin und Nephrologie</name>
      <address>
        <city>Homberg (Efze)</city>
        <zip>34576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik des Saarlandes</name>
      <address>
        <city>Homburg / Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nierenzentrum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68309</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis</name>
      <address>
        <city>Meiningen</city>
        <zip>98617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyse Mettmann</name>
      <address>
        <city>Mettmann</city>
        <zip>40822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nierenzentrum Bogenhausen</name>
      <address>
        <city>München</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologie Nettetal</name>
      <address>
        <city>Nettetal</city>
        <zip>41334</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysenzentrum Peine</name>
      <address>
        <city>Peine</city>
        <zip>31224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Innere Medizin und Nephrologie</name>
      <address>
        <city>Potsdam</city>
        <zip>14482</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Innere Medizin und Nephrologie</name>
      <address>
        <city>Quedlinburg</city>
        <zip>6484</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologische Praxis Schwetzingen</name>
      <address>
        <city>Schwetzingen</city>
        <zip>68723</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHV-Dialysezentrum Siegen</name>
      <address>
        <city>Siegen</city>
        <zip>57076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologisches Zentrum</name>
      <address>
        <city>Villingen Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Worms</name>
      <address>
        <city>Worms</city>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <results_first_submitted>April 19, 2013</results_first_submitted>
  <results_first_submitted_qc>April 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2013</results_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lanthanum Carbonate</title>
          <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Information was missing</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set included all screened subjects who took at least 1 dose of lanthanum carbonate and for whom 1 follow-up assessment was completed (n = 61).</population>
      <group_list>
        <group group_id="B1">
          <title>Lanthanum Carbonate</title>
          <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.0" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All screened subjects</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects That Achieved Controlled Serum Phosphorous Levels on Calcium-based Phosphate Binder Therapy</title>
        <description>Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL.</description>
        <time_frame>Baseline</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcium-based Phosphate Binder Therapy</title>
            <description>The percent of subjects that achieved the serum phosphate KDOQI target on previous calcium-based phosphate binder therapy of &gt;=3 months of treatment prior to receiving lanthanum carbonate treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Achieved Controlled Serum Phosphorous Levels on Calcium-based Phosphate Binder Therapy</title>
          <description>Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL.</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="6.2" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects That Achieved Controlled Serum Calcium Levels on Calcium-based Phosphate Binder Therapy</title>
        <description>Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL.</description>
        <time_frame>Baseline</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcium-based Phosphate Binder Therapy</title>
            <description>The percent of subjects that achieved the serum calcium KDOQI target on previous calcium-based phosphate binder therapy for &gt;=3 months prior to receiving lanthanum carbonate treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Achieved Controlled Serum Calcium Levels on Calcium-based Phosphate Binder Therapy</title>
          <description>Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL.</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="52.9" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects That Achieved Controlled Serum Calcium Levels on Lanthanum Carbonate Therapy</title>
        <description>Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL.</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>The percent of subjects that achieved the serum calcium KDOQI target on lanthanum carbonate after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Achieved Controlled Serum Calcium Levels on Lanthanum Carbonate Therapy</title>
          <description>Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL.</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" lower_limit="36.1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects That Achieved Controlled Serum Calcium-Phosphorous Product Levels on Calcium-based Phosphate Binder Therapy</title>
        <description>Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of &lt;55 mg^2/dL^2.</description>
        <time_frame>Baseline</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcium-based Phosphate Binder Therapy</title>
            <description>The percent of subjects that achieved the serum calcium-phosphorous product KDOQI target on previous calcium-based phosphate binder therapy for &gt;=3 months prior to receiving lanthanum carbonate treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Achieved Controlled Serum Calcium-Phosphorous Product Levels on Calcium-based Phosphate Binder Therapy</title>
          <description>Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of &lt;55 mg^2/dL^2.</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" lower_limit="28.3" upper_limit="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects That Achieved Controlled Serum Calcium-Phosphorous Product Levels on Lanthanum Carbonate Therapy</title>
        <description>Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of &lt;55 mg^2/dL^2.</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>The percent of subjects that achieved the serum calcium-phosphorous product levels KDOQI target on lanthanum carbonate after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Achieved Controlled Serum Calcium-Phosphorous Product Levels on Lanthanum Carbonate Therapy</title>
          <description>Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of &lt;55 mg^2/dL^2.</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="58.8" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects That Maintained Control of Serum Phosphorous Levels on Lanthanum Carbonate</title>
        <description>Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL.</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>The percent of subjects that maintained the serum phosphorous KDOQI target on lanthanum carbonate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Maintained Control of Serum Phosphorous Levels on Lanthanum Carbonate</title>
          <description>Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL.</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1 quarter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects That Maintained Control of Serum Calcium Levels on Lanthanum Carbonate</title>
        <description>Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL.</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>The percent of subjects that maintained the serum calcium KDOQI target on lanthanum carbonate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Maintained Control of Serum Calcium Levels on Lanthanum Carbonate</title>
          <description>Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL.</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1 quarter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects That Maintained Control of Serum Calcium-Phosphorous Product Levels on Lanthanum Carbonate Therapy</title>
        <description>Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of &lt;55 mg^2/dL^2.</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>The percent of subjects that maintained the serum calcium-phosphorous product KDOQI target on lanthanum carbonate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Maintained Control of Serum Calcium-Phosphorous Product Levels on Lanthanum Carbonate Therapy</title>
          <description>Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of &lt;55 mg^2/dL^2.</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1 quarter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects That Achieved Controlled Serum Phosphorous Levels on Lanthanum Carbonate</title>
        <description>Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL.</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>The percent of subjects that achieved the serum phosphate KDOQI target on lanthanum carbonate after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Achieved Controlled Serum Phosphorous Levels on Lanthanum Carbonate</title>
          <description>Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL.</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="24.9" upper_limit="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects That Maintained Control of Intact Parathyroid Hormone (iPTH) Levels on Lanthanum Carbonate Therapy</title>
        <description>iPTH levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for iPTH of 150-300 pg/mL</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>The percent of subjects that maintained the iPTH KDOQI target on lanthanum carbonate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Maintained Control of Intact Parathyroid Hormone (iPTH) Levels on Lanthanum Carbonate Therapy</title>
          <description>iPTH levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for iPTH of 150-300 pg/mL</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1 quarter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 consecutive quarters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Phosphorous Levels at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Phosphorous Levels at 12 Months</title>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percent change in phosphorous levels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Calcium Levels at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Calcium Levels at 12 Months</title>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percent change in calcium levels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Calcium-Phosphorous Product Levels at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Calcium-Phosphorous Product Levels at 12 Months</title>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percent change in calcium-phosphorous</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in iPTH Levels at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in iPTH Levels at 12 Months</title>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percent change in iPTH levels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" spread="393.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in 25-Hydroxy Vitamin D Levels at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. Note that there are a high number of missing values (n=36) for this outcome which does not allow for any meaningful comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in 25-Hydroxy Vitamin D Levels at 12 Months</title>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. Note that there are a high number of missing values (n=36) for this outcome which does not allow for any meaningful comparison.</population>
          <units>percent change in vitamin D</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in 1,25-Hydroxy Vitamin D Levels at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. Note that there are a high number of missing values (n=38) for this outcome which does not allow for any meaningful comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in 1,25-Hydroxy Vitamin D Levels at 12 Months</title>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. Note that there are a high number of missing values (n=38) for this outcome which does not allow for any meaningful comparison.</population>
          <units>percent change in vitamin D</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Hypocalcemic Events on Calcium-based Phosphate Binder Therapy</title>
        <description>Hypocalcemia is defined as serum calcium levels below 8.02 mg/dL</description>
        <time_frame>Baseline</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcium-based Phosphate Binder Therapy</title>
            <description>Calcium-based phosphate binder therapy of &gt;=3 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With Hypocalcemic Events on Calcium-based Phosphate Binder Therapy</title>
          <description>Hypocalcemia is defined as serum calcium levels below 8.02 mg/dL</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Hypocalcemic Events on Lanthanum Carbonate</title>
        <description>Hypocalcemia is defined as serum calcium levels below 8.02 mg/dL</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With Hypocalcemic Events on Lanthanum Carbonate</title>
          <description>Hypocalcemia is defined as serum calcium levels below 8.02 mg/dL</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Hypercalcemic Events on Calcium-based Phosphate Binder Therapy</title>
        <description>Hypercalcemia is defined as total serum calcium level above 11.22 mg/dL.</description>
        <time_frame>Baseline</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcium-based Phosphate Binder Therapy</title>
            <description>Calcium-based phosphate binder therapy for &gt;=3 months prior.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With Hypercalcemic Events on Calcium-based Phosphate Binder Therapy</title>
          <description>Hypercalcemia is defined as total serum calcium level above 11.22 mg/dL.</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Hypercalcemic Events on Lanthanum Carbonate</title>
        <description>Hypercalcemia defined as total serum calcium above 11.22 mg/dL</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With Hypercalcemic Events on Lanthanum Carbonate</title>
          <description>Hypercalcemia defined as total serum calcium above 11.22 mg/dL</description>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vitamin D Dose at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vitamin D Dose at 12 Months</title>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>ng</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.0075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Total Daily Dose of Calcium at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Total Daily Dose of Calcium at 12 Months</title>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-178.6" spread="437.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Tablets Per Day</title>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior</population>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate</title>
            <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Tablets Per Day</title>
          <population>Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior</population>
          <units>Number of Tablets</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Analysis Set (n = 61)</desc>
      <group_list>
        <group group_id="E1">
          <title>Lanthanum Carbonate</title>
          <description>Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for &gt;=3 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire Development LLC</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

